Comparison of different doses of Dexmedetomidine in elderly patients undergoing retrograde cholangiopancreatography

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054726

Enrollment

Unknown

Registered

2021-12-25

Start date

2022-01-01

Completion date

Unknown

Last updated

2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliopancreatic system disease

Interventions

control group:No maintenance dose of Dexmedetomidine

experimental group 1:Low maintenance dose of Dexmedetomidine

experimental group 2:High maintenance dose of Dexmedetomidine

Eligibility

Sex/Gender

All

Age

60 Years to 89 Years

Inclusion criteria

Inclusion criteria: 1. Age 60-89 years; 2. ASA classification I-III; 3. Patients who plan to undergo ERCP.

Exclusion criteria

Exclusion criteria: 1. Allergic to experimental drugs; 2. Preoperative complicated with severe cardiovascular and respiratory system disease and severe liver and kidney insufficiency; 3. BMI >= 28kg/m^2; 4. Glaucoma, sick sinus syndrome, sinus bradycardia, conduction block; 5. Severe neuropsychiatric disease or disorder of consciousness, unable to cooperate, and excessive mental stress; 6. Drug and alcohol dependence; 7. Abnormal airway, hearing and intellectual communication impairment; 8. Long-term use of sedatives or opioids; 9. The operation time is less than or equal to 30min.

Design outcomes

Primary

Measure	Time frame
Sedation score;	—

Countries

China

Contacts

Public ContactLuo Xin

Beijing Friendship Hospital, Capital Medical University

luoxin1989@yeah.net+86 15901283925

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026